Quantcast

Latest Curis Inc. Stories

2014-04-08 04:22:04

- Debio 0932 demonstrated anti-tumor activity and synergy with various SOC agents in in vitro and xenograft models of NSCLC and RCC - LAUSANNE, Switzerland and LEXINGTON, Mass., April 8, 2014 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription...

2009-08-06 08:00:00

CAMBRIDGE, Massachusetts and LAUSANNE, Switzerland, August 6 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing proprietary targeted medicines for cancer treatment and Debiopharm Group (Debiopharm), a group of companies with a focus on the development of prescription drugs that target unmet medical needs today announced that they have entered into a worldwide, exclusive license agreement for Curis' Heat Shock Protein (Hsp90) technology, including...

2008-10-23 09:00:38

Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing the next generation of proprietary targeted medicines for cancer treatment, today announced that the Company will be presenting at the 7th Annual BIO Investor Forum Conference, at 3:45 p.m. local time (6:45 p.m. EDT) on October 30, 2008, at the Palace Hotel in San Francisco, California. Daniel R. Passeri, Curis' President and Chief Executive Officer, will provide an overview of the status of GDC-0449, an...

2008-10-21 09:00:53

Curis, Inc. (NASDAQ:CRIS), a drug development company focused on developing proprietary targeted medicines primarily for cancer treatment, today announced that the Company will release its second quarter financial results on Tuesday, October 28, 2008 before the market opens. The Company will also hold a conference call on the same day at 10:00 A.M. Eastern time to discuss: (i) its Hedgehog antagonist program under collaboration with Genentech, (ii) CUDC-101, CUDC-305 and other proprietary...

2008-10-16 09:00:42

Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing the next generation of proprietary targeted medicines for cancer treatment, today announced that the Company will be presenting at the 2008 Boston Biotech R&D Conference, at 9:00 a.m. EDT on October 22, 2008, at Harvard Medical School in Cambridge, Mass. Daniel R. Passeri, Curis' President and Chief Executive Officer, will provide an overview of the status of GDC-0449, an orally-administered small molecule...

2008-08-28 09:01:23

Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing the next generation of proprietary targeted medicines for cancer treatment, today announced that its collaborator Genentech, Inc. has indicated that it expects to initiate a Phase II clinical trial of GDC-0449, an orally-administered small molecule Hedgehog antagonist, as a maintenance therapy for ovarian cancer patients in second or third complete remission. Genentech is developing GDC-0449 under a collaboration...

2008-08-27 15:01:10

Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing next generation proprietary targeted medicines for cancer treatment, today announced the publication of preclinical data in Nature that support the premise that Hedgehog proteins play an important role in supporting tumor growth in Hedgehog-expressing solid tumors through a paracrine mechanism of action. The paper reported that analysis of human tissue samples by Genentech scientists revealed that subsets of...

2008-08-26 09:01:20

Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing next generation proprietary targeted medicines for cancer treatment, today announced that the first patient has been treated in a Phase I clinical trial of CUDC-101, a first-in-class small molecule drug candidate that has been designed as an inhibitor of epidermal growth factor receptor (EGFR), epidermal growth factor receptor 2 (Her2) and histone deacetylase (HDAC). CUDC-101 has been designed to simultaneously...


Word of the Day
baudekin
  • A rich embroidered or brocaded silk fabric woven originally with a warp of gold thread.
'Baudekin' seems to be an alternative form of 'baldachin,' from the Italian 'Baldacco,' Baghdad, the city where the material was made.
Related